Breaking News

Tweet TWEET

Cordis Announces Additional Sizes of SLEEK® OTW Platform

  Cordis Announces Additional Sizes of SLEEK® OTW Platform

Business Wire

FREMONT, Calif. -- June 24, 2013

Cordis Corporation announced the European CE marking and U.S. Food and Drug
Administration (FDA) approval of additional sizes of its SLEEK® OTW platform,
a 0.014 inch ultra-low profile percutaneous transluminal angioplasty (PTA)
dilatation catheter. The Cordis SLEEK® OTW PTA Dilatation Catheter is a highly
deliverable balloon catheter designed to treat patients undergoing peripheral
angioplasty procedures below the knee. The SLEEK® OTW catheter was first
launched around the world in 2011. Cordis will start commercializing these new
sizes immediately in various countries around the world.

Lower limb amputation is a last resort for many patients with end-stage
peripheral arterial disease (PAD). It is estimated that as many as 160,000
lower limbs are amputated every year in the U.S. and 60-70 percent of these
amputations are performed as the first-line therapy. These lower-limb
amputations come with a mortality rate of as much as 70 percent at five years.

The SLEEK® OTW catheter has a unique balance of excellent pushability with a
small crossing profile that helps physicians restore blood flow to the lower
limbs. As part of the product line extension, Cordis now offers additional
lengths of 20mm and 280mm for most of its current diameters. The new 280mm
length will enable physicians to treat diffuse disease with fewer inflations.
The SLEEK® OTW catheter continues to be the only peripheral balloon offering
an ultra low profile 1.25mm diameter option. The addition of these sizes now
means that the Cordis SLEEK® OTW platform offers physicians the broadest 0.014
over-the-wire catheter portfolio on the market.

“The SLEEK® OTW catheter has enabled me to treat patients with severe chronic
limb ischemia using the Angiosome Concept. Now, more than ever, with the new
expanded sizes, we will be able to effectively treat extremely distal lower
leg peripheral vascular disease using fewer inflations,” said William Wu, M.D.
from the Heart and Vascular Clinic of San Antonio. “I look forward to continue
working with Cordis as they bring more products to market that will help
provide safe and optimal outcomes for patients.”

About Cordis Corporation

Cordis Corporation, part of the Johnson & Johnson Family of Companies, is a
worldwide leader in the development and manufacture of interventional vascular
technology. Through the company's innovation, research and development, Cordis
partners with physicians worldwide to treat millions of patients who suffer
from vascular disease. More information about Cordis Corporation can be found
at www.cordis.com (this site is intended for U.S. visitors).

Contact:

Media
For Cordis Corporation
Janet Kim, 909-839-7275
Jkim50@its.jnj.com
 
Press spacebar to pause and continue. Press esc to stop.